Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
Abstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13690 |
| _version_ | 1797347373304774656 |
|---|---|
| author | Agnes Hincelin‐Mery Xavier Nicolas Cathy Cantalloube Robert Pomponio Pascale Lewanczyk Myriam Benamor Dimitry Ofengeim Emmanuel Krupka Jennifer Hsiao‐Nakamoto Amy Eastenson Nazem Atassi |
| author_facet | Agnes Hincelin‐Mery Xavier Nicolas Cathy Cantalloube Robert Pomponio Pascale Lewanczyk Myriam Benamor Dimitry Ofengeim Emmanuel Krupka Jennifer Hsiao‐Nakamoto Amy Eastenson Nazem Atassi |
| author_sort | Agnes Hincelin‐Mery |
| collection | DOAJ |
| description | Abstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled single ascending dose (SAD; part 1a); 14‐day multiple ascending dose (MAD; part 2) parts that evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SAR443820; and a separate open‐label, single‐dose part 1b (PK‐cerebrospinal fluid [CSF]) to assess SAR443820 levels in CSF. SAR443820 was well‐tolerated in healthy participants, and no treatment discontinuation related to an adverse event (AE) occurred. Most common AEs were dizziness and headache. No clinically meaningful changes were noted in laboratory values, vital signs, or electrocardiogram parameters. SAR443820 had a favorable PK profile, with plasma half‐lives (geometric mean) ranged between 5.7–8.0 h and 7.2–8.9 h after single and repeated doses, respectively. There were no major deviations from dose proportionality for maximum concentration and area under the curve across SAR443820 doses. Mean CSF‐to‐unbound plasma concentration ratio ranged from 0.8 to 1.3 over time (assessed up to 10 h postdose), indicating high brain penetrance. High levels of inhibition of activated RIPK1, as measured by decrease in pS166‐RIPK1, were achieved in both SAD and MAD parts, with a maximum median inhibition from baseline close to 90% at predose (Ctrough) after multiple dosing in MAD, reflecting a marked RIPK1 target engagement at the peripheral level. These results support further development of SAR443820 in phase II trials in amyotrophic lateral sclerosis (NCT05237284) and multiple sclerosis (NCT05630547). |
| first_indexed | 2024-03-08T11:46:49Z |
| format | Article |
| id | doaj.art-c0c40af6a8594157bbb4aea061f8bfae |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-03-08T11:46:49Z |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-c0c40af6a8594157bbb4aea061f8bfae2024-01-24T18:33:50ZengWileyClinical and Translational Science1752-80541752-80622024-01-01171n/an/a10.1111/cts.13690Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participantsAgnes Hincelin‐Mery0Xavier Nicolas1Cathy Cantalloube2Robert Pomponio3Pascale Lewanczyk4Myriam Benamor5Dimitry Ofengeim6Emmanuel Krupka7Jennifer Hsiao‐Nakamoto8Amy Eastenson9Nazem Atassi10Sanofi Chilly‐Mazarin FranceSanofi Montpellier FranceSanofi Chilly‐Mazarin FranceSanofi Cambridge Massachusetts USAIvidata Life Sciences Levallois‐Perret FranceSanofi Chilly‐Mazarin FranceSanofi Cambridge Massachusetts USASanofi Montpellier FranceDenali Therapeutics Inc. South San Francisco California USANucleus Network Pty Ltd. St. Paul Minnesota USASanofi Cambridge Massachusetts USAAbstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled single ascending dose (SAD; part 1a); 14‐day multiple ascending dose (MAD; part 2) parts that evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SAR443820; and a separate open‐label, single‐dose part 1b (PK‐cerebrospinal fluid [CSF]) to assess SAR443820 levels in CSF. SAR443820 was well‐tolerated in healthy participants, and no treatment discontinuation related to an adverse event (AE) occurred. Most common AEs were dizziness and headache. No clinically meaningful changes were noted in laboratory values, vital signs, or electrocardiogram parameters. SAR443820 had a favorable PK profile, with plasma half‐lives (geometric mean) ranged between 5.7–8.0 h and 7.2–8.9 h after single and repeated doses, respectively. There were no major deviations from dose proportionality for maximum concentration and area under the curve across SAR443820 doses. Mean CSF‐to‐unbound plasma concentration ratio ranged from 0.8 to 1.3 over time (assessed up to 10 h postdose), indicating high brain penetrance. High levels of inhibition of activated RIPK1, as measured by decrease in pS166‐RIPK1, were achieved in both SAD and MAD parts, with a maximum median inhibition from baseline close to 90% at predose (Ctrough) after multiple dosing in MAD, reflecting a marked RIPK1 target engagement at the peripheral level. These results support further development of SAR443820 in phase II trials in amyotrophic lateral sclerosis (NCT05237284) and multiple sclerosis (NCT05630547).https://doi.org/10.1111/cts.13690 |
| spellingShingle | Agnes Hincelin‐Mery Xavier Nicolas Cathy Cantalloube Robert Pomponio Pascale Lewanczyk Myriam Benamor Dimitry Ofengeim Emmanuel Krupka Jennifer Hsiao‐Nakamoto Amy Eastenson Nazem Atassi Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants Clinical and Translational Science |
| title | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants |
| title_full | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants |
| title_fullStr | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants |
| title_full_unstemmed | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants |
| title_short | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants |
| title_sort | safety pharmacokinetics and target engagement of a brain penetrant ripk1 inhibitor sar443820 dnl788 in healthy adult participants |
| url | https://doi.org/10.1111/cts.13690 |
| work_keys_str_mv | AT agneshincelinmery safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT xaviernicolas safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT cathycantalloube safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT robertpomponio safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT pascalelewanczyk safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT myriambenamor safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT dimitryofengeim safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT emmanuelkrupka safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT jenniferhsiaonakamoto safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT amyeastenson safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants AT nazematassi safetypharmacokineticsandtargetengagementofabrainpenetrantripk1inhibitorsar443820dnl788inhealthyadultparticipants |